The effect of salimarin in patients with multiple sclerosis
Phase 2
- Conditions
- Condition 1: Multiple Sclerosis. Condition 2: Liver disease.Multiple sclerosisOther diseases of liver
- Registration Number
- IRCT20150628022956N7
- Lead Sponsor
- Research Council of Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Patients who have had at least 3 weeks of onset of corticosteroid attack and received corticosteroids with liver enzymes following corticosteroid therapy.
New Patients Receive Fingolimod
Patients who are taking interferon and Glatiramer are advised to take the Fingolimod, provided they have no liver problem.
Expanded Disability Status Scale below three.
Exclusion Criteria
Pregnant and lactating women
Patients who are allergic to Silymarin
Patients with previous history of tuberculosis, HIV, hepatitis and liver problems.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver complications. Timepoint: At the beginning of the study (before the intervention) and 30, 60, 90, 120, 150 and 180 days after taking Silymarin. Method of measurement: Malondialdehyde index with Ohkawa method- Total antioxidant capacity index with FRAP method- Measurement of protein thiol groups with Ellman's Reagent (DTNB).
- Secondary Outcome Measures
Name Time Method